Mersana Therapeutics/$MRSN
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Mersana Therapeutics
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Ticker
$MRSN
Sector
Health
Primary listing
Employees
102
Headquarters
Website
MRSN Metrics
BasicAdvanced
$30M
-
-$15.01
0.78
-
Price and volume
Market cap
$30M
Beta
0.78
52-week high
$7.60
52-week low
$5.85
Financial strength
Current ratio
1.826
Quick ratio
1.759
Long term debt to equity
-26.445
Total debt to equity
-79.772
Interest coverage (TTM)
-21.07%
Profitability
EBITDA (TTM)
-75.326
Gross margin (TTM)
-113.71%
Net profit margin (TTM)
-217.64%
Operating margin (TTM)
-225.98%
Effective tax rate (TTM)
-0.57%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-30.90%
Return on equity (TTM)
5,134.17%
Valuation
Price to revenue (TTM)
0.866
Price to book
-0.96
Price to tangible book (TTM)
-0.96
Price to free cash flow (TTM)
-0.373
Free cash flow yield (TTM)
-268.34%
Free cash flow per share (TTM)
-16.02
Growth
Revenue change (TTM)
-11.21%
Earnings per share change (TTM)
-46.85%
3-year revenue growth (CAGR)
154.29%
3-year earnings per share growth (CAGR)
-37.77%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mersana Therapeutics stock?
Mersana Therapeutics (MRSN) has a market cap of $30M as of August 12, 2025.
What is the P/E ratio for Mersana Therapeutics stock?
The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of August 12, 2025.
Does Mersana Therapeutics stock pay dividends?
No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of August 12, 2025.
When is the next Mersana Therapeutics dividend payment date?
Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for Mersana Therapeutics?
Mersana Therapeutics (MRSN) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.